Suppr超能文献

术前纤维蛋白原-白蛋白比值对行直接经皮冠状动脉介入治疗的急性 ST 段抬高型心肌梗死患者死亡率的影响。

The impact of preoperative fibrinogen-albumin ratio on mortality in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

机构信息

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Clin Chim Acta. 2019 Jun;493:8-13. doi: 10.1016/j.cca.2019.02.018. Epub 2019 Feb 20.

Abstract

BACKGROUND

We investigated the prognostic value of fibrinogen-albumin ratio (FAR) in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) based on inflammation and hemorheology alterations and to determine whether FAR can supplement incremental predictive information to the Global Registry of Acute Coronary Events (GRACE) score.

METHODS

We retrospectively analyzed 475 STEMI patients undergoing pPCI. Kaplan-Meier curve, Cox proportional hazards regression model, and Hosmer-Lemeshow test were used to evaluate the prognostic value of FAR in the patients.

RESULTS

Patients were assigned to groups of high FAR (≥0.080) vs low FAR (<0.080) based on the optimal cutoff value of 0.080. In all, 59 patients (12.4%) died; the mortality rate was higher in high FAR patients than in low FAR patients (20.5% vs. 8.6%, p < .001). FAR positively correlated with C-reactive protein, GRACE score, and Gensini score (p < .001). On multivariate analysis, FAR was an independent prognostic factor in STEMI patients undergoing pPCI. Accordingly, adding FAR to the GRACE score improved the C-index, net reclassification index, and integrated discrimination improvement.

CONCLUSIONS

Preoperative FAR is an independent prognostic factor in STEMI patients undergoing pPCI and might improve risk stratification in STEMI.

摘要

背景

我们基于炎症和血液流变学改变,研究了纤维蛋白原-白蛋白比值(FAR)在接受直接经皮冠状动脉介入治疗(pPCI)的急性 ST 段抬高型心肌梗死(STEMI)患者中的预后价值,并确定 FAR 是否可以为全球急性冠状动脉事件登记(GRACE)评分提供补充的增量预测信息。

方法

我们回顾性分析了 475 例接受 pPCI 的 STEMI 患者。Kaplan-Meier 曲线、Cox 比例风险回归模型和 Hosmer-Lemeshow 检验用于评估 FAR 在患者中的预后价值。

结果

根据 0.080 的最佳截断值,患者被分为 FAR 较高(≥0.080)和 FAR 较低(<0.080)组。共有 59 例(12.4%)患者死亡;FAR 较高组的死亡率高于 FAR 较低组(20.5% vs. 8.6%,p<0.001)。FAR 与 C 反应蛋白、GRACE 评分和 Gensini 评分呈正相关(p<0.001)。多变量分析显示,FAR 是 pPCI 治疗的 STEMI 患者的独立预后因素。因此,将 FAR 添加到 GRACE 评分中可以提高 C 指数、净重新分类指数和综合判别改善。

结论

术前 FAR 是接受 pPCI 的 STEMI 患者的独立预后因素,可能改善 STEMI 的风险分层。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验